← back to search

Derin B. Keskin

Harvard University · US
Area of research
Immunology · Molecular Biology
Research interest
Research interests include Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Cancer Immunotherapy and Biomarkers, and vaccines and immunoinformatics approaches.
h-index
44
citations
14,936
works
273
NIH funding
primary concept
Biology
email

Recent publications

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma
Nature 2025cited by 153position: middledoi
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Cell 2025cited by 49position: middledoi
Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination
Nature Nanotechnology 2024cited by 151position: middledoi
Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation
Nature Biotechnology 2024cited by 16position: middledoi
CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness
Science Advances 2024cited by 9position: middledoi
Design of Cytotoxic T Cell Epitopes by Machine Learning of Human Degrons
ACS Central Science 2024cited by 3position: middledoi
Dictionary of immune responses to cytokines at single-cell resolution
Nature 2023cited by 323position: middledoi
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
Nature Cancer 2023cited by 41position: middledoi
Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
Frontiers in Oncology 2023cited by 30position: middledoi
YAP1 and WWTR1 expression inversely correlates with neuroendocrine markers in Merkel cell carcinoma
Journal of Clinical Investigation 2023cited by 28position: middledoi
Landscape of helper and regulatory antitumour CD4+ T cells in melanoma
Nature 2022cited by 186position: middledoi
Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
Clinical Cancer Research 2022cited by 35position: middledoi
Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma
Journal of Clinical Investigation 2022cited by 29position: lastdoi
Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders
Frontiers in Immunology 2022cited by 8position: middledoi
HLA-I immunopeptidome profiling of human cells infected with high-containment enveloped viruses
STAR Protocols 2022cited by 4position: middledoi
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Nature 2021cited by 537position: middledoi
Progressive immune dysfunction with advancing disease stage in renal cell carcinoma
Cancer Cell 2021cited by 505position: middledoi
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Nature Medicine 2021cited by 502position: middledoi
Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer
Nature Biotechnology 2021cited by 295position: middledoi
Profiling SARS-CoV-2 HLA-I peptidome reveals T cell epitopes from out-of-frame ORFs
Cell 2021cited by 165position: middledoi
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy
Cell Reports 2021cited by 58position: middledoi
Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples
Molecular & Cellular Proteomics 2021cited by 57position: middledoi
TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes
BMC Bioinformatics 2021cited by 50position: middledoi
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
Nature Reviews Clinical Oncology 2020cited by 284position: middledoi
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy
Scientific Reports 2020cited by 31position: middledoi
A large peptidome dataset improves HLA class I epitope prediction across most of the human population
Nature Biotechnology 2019cited by 534position: lastdoi
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies
Cancer Cell 2019cited by 358position: middledoi
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Nature 2018cited by 1,415position: firstdoi
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade
Cell 2018cited by 170position: middledoi
Detecting neoepitope-specific intra-tumoral T cell responses in a glioblastoma patient treated with personal neoantigen vaccine
The Journal of Immunology 2018cited by 0position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Catherine J. Wu · Dana-Farber/Harvard Cancer Center12 papers (2014–2024)Nir Hacohen · Broad Institute7 papers (2014–2023)Donna Neuberg · Massachusetts General Hospital6 papers (2014–2024)Ellis L. Reinherz · Northeastern University6 papers (2012–2017)Steven A. Carr · Broad Institute4 papers (2017–2022)Kenneth J. Livak · Broad Institute4 papers (2018–2022)Vladimir Brusić · University of Nottingham Ningbo China4 papers (2013–2021)Guang Lan Zhang · Boston University4 papers (2013–2019)Karl R. Clauser · Broad Institute3 papers (2017–2021)Phuong M. Le · Thomas Jefferson University3 papers (2019–2022)Jennifer G. Abelin · Massachusetts Institute of Technology3 papers (2017–2022)Susan Klaeger · Broad Institute3 papers (2019–2022)Patrick A. Ott · Harvard University3 papers (2018–2021)Guanglan Zhang · Boston University3 papers (2017–2022)David A. Braun · Yale New Haven Hospital3 papers (2019–2021)Siranush Sarkizova · Moderna Therapeutics (United States)3 papers (2017–2021)Lou Chitkushev · Boston University3 papers (2013–2021)Angelika B. Riemer · German Cancer Research Center3 papers (2012–2014)Nicholas L. Truex · University of California System2 papers (2020–2024)Giacomo Oliveira · Harvard University2 papers (2019–2021)